Unveiling the Subtypes: How Treatment Selection Transforms Dry Eye Management
In the realm of dry eye disease (DED), experts are unraveling the intricacies of treatment selection, emphasizing the pivotal role of subtype differentiation. The "Reimagining Dry Eye Management: Targeting Tear Function for Sustained Relief" series, moderated by Kendall Donaldson, MD, MS, brings together a panel of renowned professionals: Cecelia Koetting, OD, FAAO; Selina McGee, OD, FAAO; and Karl Stonecipher, MD. This thought-provoking discussion delves into the core of diagnosis and management, highlighting the critical need to identify the underlying causes and distinguish between aqueous-deficient and evaporative dry eye types.
The panel's exploration of tear composition and patient-specific factors reveals the intricate dance of therapeutic decisions. They shed light on the common patient frustration with limited or temporary relief from traditional treatments. As the conversation shifts, the focus turns to groundbreaking therapies targeting tear function and ocular surface homeostasis. The experts scrutinize novel treatments, including perfluorohexyloctane (Miebo), cyclosporine ophthalmic solution 0.1% (Vevye), and the recently FDA-approved acoltremon ophthalmic solution (Tryptyr), a TRPM8 agonist. They delve into the mechanisms, efficacy, and tolerability of these treatments, considering the potential of neurogenic stimulation of the lacrimal unit to enhance tear stability.
The discussion intensifies as the panel scrutinizes clinical trial outcomes, particularly the COMET-2 and COMET-3 studies, underscoring the delicate balance between objective and subjective end points, such as the Schirmer test and SANDE scores. This analysis is crucial for understanding the real-world implications of these therapies.
The conversation then transitions to the practical integration of these innovations. The experts offer insights into setting realistic patient expectations, ensuring adherence, and implementing monitoring strategies for long-term care. They explore the impact of rapid symptom relief on patient satisfaction, identify unmet needs in DED treatment, and provide guidance on incorporating new therapeutics into daily practice.
The series concludes with a powerful exchange of closing reflections from each panelist, followed by a brief media engagement that encourages peer connection and the dissemination of these valuable insights through professional networks. Don't miss out on the latest clinical advancements and expert interviews—subscribe to Ophthalmology Times for exclusive updates delivered straight to your inbox.
